The Promise and Perils of ‘Targeted Therapy’ of Advanced Ovarian Cancer

  title={The Promise and Perils of ‘Targeted Therapy’ of Advanced Ovarian Cancer},
  author={Maurie Markman},
  pages={1 - 6}
  • M. Markman
  • Published 1 June 2008
  • Medicine, Biology
  • Oncology
For several reasons, ovarian cancer is an excellent malignancy to consider the use of ‘targeted’ therapeutic strategies. However, to date, despite considerable effort, there remains limited evidence that such approaches are clinically relevant in the malignancy. The one important exception is the delivery of anti-angiogenic anti-neoplastic agents, which actually appear to be more biologically active as single drugs in ovarian cancer than in other solid tumors where they have been examined. It… 
Targeted Therapies in Epithelial Ovarian Cancer
This review examines three of the most provocative targeted therapies with current or future applicability in epithelial ovarian cancer.
Immunotherapy and targeted therapy for cervical cancer: an update
Background information on the molecular biology of cervical cancer is provided and immunotherapy studies, targeted therapies, including those with angiogenesis inhibitors and tyrosine kinase inhibitors recently completed or currently on-going in cervical cancer patients are summarized.
Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
The basis of and the logic behind the use of these agents in the treatment of epithelial ovarian cancer are discussed, as well as their evaluation in different preclinical and clinical studies.
EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.
The available data suggest that modulating the expression or activity of the EGFR and/or matrix metalloproteinases offers opportunity for targeted intervention in patients with metastatic disease.
The expression status of human epidermal growth factor receptor 2 in epithelial ovarian cancer in Ibadan , Nigeria
HER2/neu expression was observed to increase with advanced stages of cancer, and was more commonly seen in serous, rather than in mucinous, carcinomas.
Hormone–receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria
The study showed a lower ER expression in serous carcinoma compared to large cohorts from developed countries and future translational studies could be used to determine response of EOC to endocrine therapy.
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
It is concluded that targeting the IGF-IR and the PI3K pathways is a promising new strategy to treat cisplatin-resistant ovarian carcinomas.
AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
AMXI-5001 will enter clinical trial testing soon and represents a promising, novel first in class dual PARP1/2 and microtubule polymerization inhibitor that delivers continuous and synchronous one-two punch cancer therapy with one molecule.


Second-line treatment of ovarian cancer.
Strategies for management of patients with recurrent disease, including classification, treatment goals, and therapeutic options will be reviewed.
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)
  • D. Alberts, P. Liu, M. Markman
  • Medicine, Biology
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • 2007
It is concluded that imatinib mesylate as a single agent does not appear to have useful clinical activity in c-Kit and/or PDGFR positive, recurrent ovarian cancer in heavily pretreated patients with ovarian cancer.
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
We read with much interest the article by Therasse et al. (1) on the new Response Evaluation Criteria in Solid Tumors Group (RECIST) in the Journal. In the RECIST, the definition of progression is
Bevacizumab in patients with advanced platinum-resistant ovarian cancer.
BV has single agent activity in women with PROC, but is associated with substantial toxicity in this population, and trials are ongoing in less heavily treated, newly diagnosed pts with OC to evaluate the efficacy and safety of BV in these disease settings.
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
The length of a prior response to platinum-based therapy in ovarian cancer is highly predictive of the upper limit of the duration of response to a subsequent platinum program, assuming the same or similar drugs are used.
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial
5000 Background: Bev is a recombinant humanized anti-VEGF monoclonal antibody that inhibits the growth of a number of human cancers, including ovarian cancer. Low dose chronic chemotherapy (metrono...